Prevention of ovarian cancer by administration of a Vitamin D co

Details Prevention of ovarian cancer by administration of a Vitamin D co Prevention of ovarian cancer by administration of a Vitamin D co

1997-06-11

2000-03-07

Robinson, Allen J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

9,10-seco- cyclopentanohydrophenanthrene ring system doai

A61K 3159

Patent

active

060340746

ABSTRACT:
The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering a Vitamin D compound in an amount capable of increasing apoptosis in non-neoplastic ovarian epithelial cells of the female subject.

REFERENCES:
patent: 4594340 (1986-06-01), Partridge et al.
patent: 4800198 (1989-01-01), DuLuca et al.
patent: 4833125 (1989-05-01), Neer et al.
patent: 5190935 (1993-03-01), Binderup et al.
patent: 5206229 (1993-04-01), Calverley et al.
patent: 5246925 (1993-09-01), DuLuca et al.
patent: 5278155 (1994-01-01), Ikekawa et al.
patent: 5373004 (1994-12-01), DeLuca et al.
patent: 5374629 (1994-12-01), Calverly et al.
patent: 5380720 (1995-01-01), DeLuca et al.
patent: 5387582 (1995-02-01), Hansen et al.
patent: 5389622 (1995-02-01), Posner et al.
patent: 5401731 (1995-03-01), Calverley et al.
patent: 5411949 (1995-05-01), Neef et al.
patent: 5428029 (1995-06-01), Doran et al.
patent: 5446035 (1995-08-01), Neef et al.
patent: 5451574 (1995-09-01), Baggiolini et al.
patent: 5484782 (1996-01-01), DeLuca et al.
patent: 5512554 (1996-04-01), Baggiolini et al.
patent: 5532228 (1996-07-01), Neef et al.
patent: 5536713 (1996-07-01), DuLuca et al.
patent: 5547947 (1996-08-01), Dore et al.
patent: 5554599 (1996-09-01), GrueSorensen et al.
Bast and Berchuck, et al. "Ovarian Cancer," Harrison's Principles of Internal Medicine, 13.sup.th ed., Isselbacher et al., eds., 1853-1858 (1994).
Rodriguez et al., Estrogen Replacement Therapy and Fatal Ovarian Cancer, Am. J. Epidem., 141: 828-835 (1995).
Amos et al., Genetic Epidemiology of Epithelial Ovarian Cancer, Cancer, 71:566-72 (1993).
Whitmore, Characteristics Relating To Ovarian Cancer Risk: Implications for Preventing and Detection, Gynecologie Oncology 55, 515-19 (1994).
Corder et al., Cancer Epidemiology, Biomarks & Prevention 2: 467-472 (1993).
Santiso-Mere et al., Molecular Endocrinology vol. 7, No. 7, 833-39 (1993).
Davoodi et al., J. Steriod Biochem. Molec. Biol. 54: No. 3/4, 147-153 (1995).
Colston et al., "1,25-Dihydroxyvitamin D.sub.3 and Malignant Melanoma: The Presence of Receptors and Inhibition of Cell Growth in Culture," Endocrinology vol. 108, 1083-1086 (1981).
Sato et al., "Antitumor Effect of 1.alpha.-Hydroxyvitamin D.sub.3," Tohoku J. Exp. Med. 138: 445-446 (1982).
Eisman et al., "Suppression of in Vivo Growth of Human Cancer Solid Tumor Xenografts by 1, 25-Dihydroxyvitamin D.sub.3," Cancer Research 47: 21-25 (1987).
Dokoh et al., Influence of 1, 25-Dihydroxyvitamin D.sub.3 on Cultured Osteogenic Sarcoma Cells: Correlations with the 1, 25-Dihydroxyvitamin D.sub.3 Receptor, Cancer Research 44: 2103-2109 (1984).
Mangelsdorf et al., "1,25-Dihydroxyvitamin D.sub.3 -induced Differentiation in a Human Promyelocytic Leukemia Cell Line(HL-60)," J. Cell Biol. vol. 98, 391-398 (1984).
Chida et al., "Inhibition of Tumor in Mouse Skin by .alpha.,25-Dihydroxyvitamin D.sub.3," Cancer Research 45: 5426-5430 (1985).
Oikawa et al., "Antitumor effect of 22-oxa-1.alpha.,25-dihydroxyvitamin D.sub.3 a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene," Anti-Cancer Drugs 2: 475-480 (1991).
Frampton et al., "Inhibition of Human Cancer Cell Growth by 1,25-Dihydroxyvitamin D.sub.3 Metabolites," Cancer Research 43: 4443-4447 (1983).
Sporn et al., "Prevention of Carciogenesis With Vitamin D Analogs" Proc. Am. Assn. Cancer Res., No. 34, Abstracts, 622 (Mar. 1993).
Christopherson et al., "Responsiveness of Human Carcinoma Cells of Gynecologic Origin to 1,25-Dihydroxycholecalciferol" Am. J. Obstet Gynecol., vol. 155, No. 6., 1293-1296 (1986).
Saunders et al., "Receptors for 1,25-Dihydroxyvitamin D.sub.3 in Gynecologic Neoplasms" Gynecologic Oncology 44: 131-136 (1992).
Saunders et al., "Additive Inhibition of RL95-2 Endometrial Carcinoma Cell Growth by Carboplatin and 1,25 Dihydroxyvitamin D.sub.3 " Gynecologic Oncology 51: 155-159 (1993).
Saunders et al., "Inhibition of Breast and Ovarian Carcinoma Cell Growth By 1,25-Dihydroxyvitamin D.sub.3 Combined With Retinoic Acid or Dexamethansone" AntiCancer Drugs 6: 562-569 (1995).
Welsh, "Induction of Apoptosis in Breast Cancer Cells in Response to Vitamin D and Antiestrogens" Biochem. Cell Biol. 72: 537-545 (1994).
Narvaez et al., "Characterization of a Vitamin D.sub.3 -Resistant MCF-7 Cell Line" Endocrinology vol. 137, No. 2, 400-409 (1996).
Lefkowitz et al., Sunlight, Vitamin D, and Ovarian Cancer Mortality Rates in US Woman International Journal of Epidemiology vol. 23, No. 6, 1133-1136 (1994).
Studzinski et al., "Sunlight-Can it Prevent as well as Cause Cancer?" Cancer Research 55:4014-4022 (1995).
R. Lockshin, Z. Zakeri, "The Biology of Cell Death and Its Relationship to Aging," Cellular Aging and Cell Death, N.J. Holbrook, G. Martin, R. Lockshin, eds., 167-180 (1996).
C. Milligan, L. Schwartz, "Programmed Cell Death During Development of Animals in Cellular Aging and Cell Death," Cellular Aging and Cell Death, N.J. Holbrook, G. Martin, R. Lockshin, eds., 181-208 (1996).
S. Lowe, H. E. Ruley, "p53-Dependent Apoptosis in Tumor Progression and in Cancer Therapy," Cellular Aging and Cell Death, N.J. Holbrook, G. Martin, R. Lockshin, eds., 209-234, (1996).
Canman et al., "DNA Damage Responses: p53 Induction, Cell Cycle Pertubations, and Apoptosis," Cold Spring Harbor Symp. Quant. Biol., 59: 277-286 (1994).
Speroff et al., Clinical Gynecologic Endocrinology and Infertility (Chap. 15, "Steroid Contraception"), 4.sup.th Ed., 461-498 (1989).
Hammond, "Climacteric," Danforth's Obstetrics and Gynecology, Chapter 42, 7.sup.th Ed., 771-790 (1994).
Remington's Pharmaceutical Sciences, Chapters 75-92, 18.sup.th Ed. 1435-1712 (1990.
Baker et al., "Etiology, Biology, and Epidemiology of Ovarian Cancer," Seminars in Surgical Oncology 10: 242-248 (1994).
Rosenblatt et al., "High-dose and Low-dose Combined Oral Contraceptives: Protection Against Epithlial Ovarian Cancer and The Length of the Protective Effect," Eur. J. Cancer, 28A: 1872-76, (1992).
Stanford and Thomas, "Depot-Medroxyprogesterone Acetate (DMPA) and Risk of Epithelial Ovarian Cancer," Int'l J. Cancer, 49: 191-195 (1991).
Liang et al., "Risk of Breast, Uterine Corpus, and Ovarian Cancer in Women Receiving Medroxyprogesterone Injections," JAMA, 249: 2909-2912 (1983).
Young "Gynecologic Malignancies, Ovarian Cancer," Harrison's Principles of Internal Medicine, 13.sup.th ed., 605-08 (1994).
Wu et al., "Personal and Environmental Characteristics Relating To Epithelial Ovarian Cancer," Am. J. Epidem., 128 (6): 1216-1227 (1988).
Rossing et al., "Ovarian Tumors in a Cohort of Infertile Women," New Engl. J. Med., 331: 771-76 (1994).
Casagrande et al., "`Incessant Ovulation` and Ovarian Cancer," The Lancet, 170-72 (Jul. 28, 1979).
Rosenberg et al., "A Case-Control Study Of Oral Contraceptive Use and Invasive Epithelial Ovarian Cancer," Am. J. Epidem., 139: 654-61 (1994).
Stanford et al., "Epithelial Ovarian Cancer and Combined Oral Contraceptives," Int'l J. Epidem., 18: 538-45 (1989).
Lee et al., "The Reduction in Risk of Ovarian Cancer Associated with Oral Contraceptive Use," New Engl. J. Med., 316: 650-55 (1987).
Gross and Schlesselman, "The Estimated Effect of Oral Contraceptive Use on the Cumulative Risk of Epithlial Ovarian Cancer," Obstetrics & Gynecology, 83: 419-24 (1994).
Franseschi et al., "Pooled Analysis of 3 European Case-Control Studies of Epithelial Ovarian Cancer: III. Oral Contraceptive Use," Int'l J. Cancer, 49: 61-65 (1991).
Greene et al., "The Epidemiology of Ovarian Cancer," Seminars in Oncology, 11: 209-225 (1984).
Wittemore et al., "Characteristics Relating To Ovarian Cancer Risk: Collaborative Analysis of 12 US Case-Control Studies," Am. J. Epidem. 136: 1212-20 (1992).
Moore, T.B. et al., "Differentiating effects of 1,25-dihydroxycholecalciferol (D3) on LA-N-5 human neuroblastoma cells and its synergy with retinoic acid," Journal of Pediatric Hematology/Oncology, 17(4):311-317 (Nov. 1995).
Rustin, G.J.S. et al., "Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer," Br. J. Cancer, 74(9):1479-1481 (1996).
Saunders, D.E.

Affiliated with

Also associated with

Rating

Prevention of ovarian cancer by administration of a Vitamin D co does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prevention of ovarian cancer by administration of a Vitamin D co, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention of ovarian cancer by administration of a Vitamin D co will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-363249